AURORA, Colo., Nov. 8, 2023 /PRNewswire/ — Foresight Diagnostics, a frontrunner in ultrasensitive minimal residual illness (MRD) detection testing, introduced at this time that six research using their patented PhasED-Seq™ know-how might be offered on the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) taking place December 9-12, 2023, in San Diego, California. Four of those research have been accepted as oral shows.
The PhasED-Seq MRD platform is a ctDNA take a look at that detects minimal residual illness (MRD) with increased ranges of sensitivity and specificity in comparison with first-generation MRD applied sciences. In sufferers with lymphomas, this might allow the sooner detection of residual illness in sufferers who’re susceptible to relapse after first-line remedy. Recent research have proven that PhasED-Seq’s sensitivity and specificity exceeds that of normal of care imaging (e.g., PET/CT) permitting for extra correct response evaluation in sufferers with DLBCL. Additionally, exploratory research have demonstrated that PhasED-Seq’s excessive sensitivity detected future relapse a median of 10 months prior to imaging.
Building upon these findings, Foresight and its companions will current new knowledge at ASH 2023 that additional helps the utility of Foresight’s ultrasensitive PhasED-Seq MRD platform for correct remedy response evaluation. These knowledge units display the prevalence of PhasED-Seq relative to plain of care PET/CT imaging for response evaluation in a number of scientific settings, in addition to its potential utility as a biomarker for remedy choice.
“We are thrilled to have been chosen by the ASH Program Committee to share knowledge from these impactful research that make the most of Foresight’s PhasED-Seq MRD know-how,” mentioned Jake Chabon, PhD, CEO and co-founder of Foresight Diagnostics. “Our objective at Foresight Diagnostics is to enhance affected person care by offering researchers with actionable knowledge and insights that we hope will pave the best way for the following technology of lymphoma care using ctDNA measures. We are notably excited by the promise of PhasED-Seq based mostly MRD evaluation as an endpoint in lymphoma scientific trials which might result in accelerated approvals of novel therapies, thus getting probably life-saving remedies to sufferers sooner. We are grateful to all of the collaborators and presenters for his or her essential work on the 2023 ASH Annual Meeting.”
Podium Presentations:
Abstract Number: 225
Abstract Title: Circulating Tumor DNA Dynamics as Early Outcome Predictors for Lisocabtagene Maraleucel as Second-Line Therapy for Large B-Cell Lymphoma from the Phase 3 TRANSFORM Study
Presenting Author: Ash Alizadeh, MD, PhD (Stanford University)
Session Date: Saturday, December 9, 2023, 2:30 PM PT, San Diego Convention Center, Room 6CF
Abstract Number: 192
Abstract Title: End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA
Presenting Author: Mark Roschewski, MD (National Cancer Institute)
Session Date: Saturday, December 9, 2023, 3:15 PM PT, Manchester Grand Hyatt San Diego, Grand Hall C
Abstract Number: 187
Abstract Title: Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy
Presenting Author: Jordan Goldstein, MD, MSc (Stanford University)
Session Date: Saturday, December 9, 2023, 2:00 PM PT, Manchester Grand Hyatt San Diego, Grand Hall C
Abstract Number: 69
Abstract Title: Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World CtDNA Study
Presenting Author: Brian Sworder, MD, PhD (University of California Irvine)
Session Date: Saturday, December 9, 2023, 10:00 AM PT, Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH
Poster Presentations:
Abstract Number: 3133
Abstract Title: Early and Sustained Circulating Tumor DNA Response Dynamics after Loncastuximab Tesirine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Presenting Author: David Kurtz, MD, PhD (Stanford University)
Session Date: Sunday, December 10, 2023, 6:00 PM – 8:00 PM PT, San Diego Convention Center, Halls G-H
Abstract Number: 1626
Abstract Title: Phased Variants Allow Robust Profiling of Circulating Tumor DNA in Untreated Follicular Lymphomas
Presenting Author: Csaba Bödör, PhD (Semmelweis University)
Session Date: Saturday, December 9, 2023, 5:30 PM – 7:30 PM PT, San Diego Convention Center, Halls G-H
For extra info, go to us at sales space #2014 or e mail us at [email protected] to rearrange a gathering.
About Foresight Diagnostics
Foresight Diagnostics is a privately held most cancers diagnostics firm and CLIA-registered laboratory. The firm has developed a novel liquid biopsy testing platform for the measurement of minimal residual illness (MRD). The improved sensitivity of the Foresight MRD assays can present actionable info to physicians and biopharmaceutical firms to allow extra personalised remedy approaches for sufferers with strong tumors and B-cell malignancies. For extra info, please go to foresight-dx.com and observe us on Twitter and LinkedIn.
About PhasED-Seq
The Foresight MRD platform relies on the Phased variant Enrichment and Detection by Sequencing (PhasED-Seq) know-how. PhasED-Seq lowers the error profile of mutation detection in sequencing knowledge by requiring the concordant detection of two separate non-reference occasions in an individual DNA molecule. By detecting a couple of mutation, PhasED-Seq can extra precisely distinguish tumor-derived cell free DNA (i.e., ctDNA) from wholesome cell free DNA – enabling detection of ctDNA at ranges beneath one part-per-million (<0.0001%). PhasED-Seq has been extensively examined in hundreds of sufferers.
Media Contact Information
720-443-3658
View authentic content material to obtain multimedia:https://www.prnewswire.com/news-releases/foresight-diagnostics-announces-six-presentations-highlighting-the-utility-of-phased-seq-for-early-and-accurate-mrd-detection-at-the-65th-american-society-of-hematology-annual-meeting-301980934.html
SOURCE Foresight Diagnostics
